We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Panbela Therapeutics Inc (PBLA) USD0.001

Sell:$1.26 Buy:$1.40 Change: $0.01 (0.71%)
Market closed |  Prices as at close on 8 August 2022 | Switch to live prices |
Sell:$1.26
Buy:$1.40
Change: $0.01 (0.71%)
Market closed |  Prices as at close on 8 August 2022 | Switch to live prices |
Sell:$1.26
Buy:$1.40
Change: $0.01 (0.71%)
Market closed |  Prices as at close on 8 August 2022 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Panbela Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing disruptive therapeutics for the treatment of patients with cancer. Its primary focus is on the treatment of patients with pancreatic cancer. Its lead product candidate, SBP-101, is a polyamine analogue designed to induce polyamine metabolic inhibition (PMI) by exploiting an observed high affinity of the compound for pancreatic ductal adenocarcinoma, ovarian cancer and other tumors. The Company is conducting Phase Ia/Ib study of the safety, tolerability and pharmacokinetics of SBP-101 when administered in combination with gemcitabine and nab-paclitaxel.

Contact details

Address:
712 Vista Blvd # 305
WACONIA
55387
United States
Telephone:
+1 (952) 4791196
Website:
www.sunbiopharma.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
PBLA
ISIN:
US69833W1071
Market cap:
$29.08 million
Shares in issue:
20.77 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Michael Cullen
    Chairman of the Board
  • Jennifer Simpson
    President, Chief Executive Officer, Director
  • Susan Horvath
    Chief Financial Officer, Vice President - Finance, Treasurer, Company Secretary

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.